CVS Health (CVS) Tops Q2 EPS by 2c; Boosts FY16 EPS Outlook

CVS Health (NYSE: CVS) reported Q2 EPS of $1.32, $0.02 better than the analyst estimate of $1.30. Revenue for the quarter came in at $43.7 billion versus the consensus estimate of $44.28 billion.

Same store sales increased 2.1% versus the second quarter of 2015. Pharmacy same store sales rose 3.9% and pharmacy same store prescription volumes rose 3.5% on a 30-day equivalent basis.

GUIDANCE:

CVS Health sees Q3 2016 EPS of $1.55-$1.58.

CVS Health sees FY2016 EPS of $5.81-$5.89, versus prior guidance of $5.73-$5.88. Raised full year cash flow from operations to $8.8 to $9.1 billion from $7.6 to $7.9 billion; free cash flow raised to $6.3 to $6.6 billion from $5.3 to $5.6 billion

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• South State Corp. (SSB) Tops Q1 EPS by 4c
• The Bancorp (TBBK) Reports In-Line Q1 EPS